ProImmune Expands Operations in Oxford
ProImmune Ltd, a significant player in the realm of life science reagents and services, proudly announced the inauguration of its new global headquarters located at Oasis Park in Oxford. This strategic move, which encompasses an 18,000 square foot facility, is set to bolster the company’s operational capacity and enhance its ability to cater to its international clientele. The establishment of this headquarters coincides with ProImmune’s recent acquisition of the expansive 70,000 sq ft Oasis Park, which is already home to several other tenants and is situated within the vibrant bioscience and innovation ecosystem of Oxford.
Investment in Innovation
The newly launched headquarters is not just about the physical space; it represents a considerable investment in advanced laboratory facilities that will facilitate the rapid development of ProImmune’s innovative products. Among these are the REVEAL® Immunogenicity System, designed to assess immune responses to vaccines and therapeutic interventions, and the cutting-edge Ankyron® target binding technologies. These Ankyron proteins, which are small, recombinant ankyrin repeat proteins, provide a novel solution to common challenges faced in antibody research. With their high specificity and reproducibility, these proteins offer a cost-effective alternative for generating custom antibodies.
Commitment to Scientific Excellence
Dr. Nikolai Schwabe, the Chief Executive Officer of ProImmune, emphasized the significance of this new headquarters, stating that it symbolizes the company’s unwavering dedication to scientific excellence in the fields of immunology and global health. He noted that the investment in both the park and the new flexible laboratory facilities enhances ProImmune’s capability to deliver top-tier products and services. This, he explained, directly supports the company’s partners in their quest to develop safer and more effective therapies for patients worldwide.
The expansion into a state-of-the-art facility at Oasis Park marks a pivotal moment for ProImmune, as it seeks to advance its research and development efforts while remaining at the forefront of innovation in the life sciences sector. As the company continues to grow, it aims to make significant contributions to the scientific community and improve health outcomes globally.
Related
